Soluble CD40 Ligand in systemic lupus erythematosus: link with atherosclerotic vascular affection
- Authors: Popkova TV1, Panafidina TA1, Aleksandrova EN1, Novikova DS1, Novikov AA1, Alekberova ZS1, Mach ÉS1, Nasonov EL1
-
Affiliations:
- ГУ Институт ревматологии РАМН, Москва
- Issue: Vol 80, No 5 (2008)
- Pages: 37-41
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30164
- ID: 30164
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
T V Popkova
ГУ Институт ревматологии РАМН, Москва
T A Panafidina
ГУ Институт ревматологии РАМН, Москва
E N Aleksandrova
ГУ Институт ревматологии РАМН, Москва
D S Novikova
ГУ Институт ревматологии РАМН, Москва
A A Novikov
ГУ Институт ревматологии РАМН, Москва
Z S Alekberova
ГУ Институт ревматологии РАМН, Москва
É S Mach
ГУ Институт ревматологии РАМН, Москва
E L Nasonov
ГУ Институт ревматологии РАМН, Москва
References
- Насонова В. А. Системная красная волчанка. М.: Изд-во "Медицина"; 1972.
- Trager J., Ward М. М. Mortality and cause of death in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2001; 13: 345-351.
- Asanuma Y., Oeser A., Shintani A. K. et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 2003; 349: 2407-2415.
- Cervera R., Khamashta M. A., Font J. et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1000 patients. Medicine (Baltimore) 1999; 78: 167-175.
- Sella E. M., Sato E. I., Barbieri A. Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthr. and Rheum. 2003; 48: 3168-3175.
- Ward M. M., Pyun E., Studenski S. Causes of death in systemic lupus erythematosus: long-term follow-up of an inception cohort. Arthr. and Rheum. 1995; 38: 1492-1499.
- Панафидина Т. А., Попкова Г. В., Алекберова З. С. Значение факторов риска и С-реактивного белка в развитии атеросклероза у женщин с системной красной волчанкой. Клин. мед. 2006; 10: 49-54.
- Ильина А. Е., Клюквина Н. Г., Александрова Е. Н. Атеросклеротическое поражение сосудов при системной красной волчанке у мужчин: связь с концентрацией С-реактивного белка. Тер. арх. 2005; 6: 61-65.
- Svenungsson Е., Witztum J. L., Frostegard J. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 103: 1887-1893.
- Manzi S., Selzer F., Kuller L. H. et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthr. and Rheum. 1999; 42: 51-60.
- Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-126.
- Насонов E. Л. (ред.). Антифосфолипидный синдром. M.: Изд-во "Литтерра"; 2004.
- Насонов Е. Л. Проблема атеротромбоза в ревматологии. Вестн. РАМН 2003; 7: 6-10.
- Насонов Е. Л., Попкова Т. В. Кардиоваскулярные проблемы ревматологии. Науч.-практ. ревматол. 2004; 4: 4-9.
- Насонов Е. Л. Иммунологические маркеры атеросклероза. Тер. арх. 2002; 5: 80-85.
- Schönbeck U., Libby P. CD40 signaling and plaque instability. Circ. Res. 2001; 89: 1092-1103.
- Phillips R. P. Atherosclerosis: the emerging role of inflammation and CD40-CD40 ligand system. Proc. Natl. Acad. Sci. USA 2000; 97: 6930-6932.
- Freedman J. E. CD40-ligand assessing risk instead of damage? N. Engl. J. Med. 2003; 348: 1163-1165.
- Kato K., Santana-Sahagun E., Rassenti L. Z. et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. 1999; 104: 947-955.
- Ferro D., Pignatelli P., Loffredo L. et al. Soluble CD154 plasma levels in patients with systemic lupus erythematosus: modulation by antiphospholipid antibodies. Arthr. and Rheum. 2004: 50: 1693-1694.
- Van Kooten С., Blanchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv. Immunol. 1996; 61: 1-77.
- André P., Nannizzi-Alaimo L., Prasad S. K. et al. Platelet-derived CD40L. The switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-899.
- Vakkalanka R. К., Woo С, Kiron К. A. et al. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthr. and Rheum. 1999; 42: 871-881.
- Александрова E. Н., Новиков А. А., Попкова Т. В. Растворимый лиганд CD40 при системной красной волчанке и антифосфолипидном синдроме. Тер. арх. 2006; 10: 49-5.
- Hochberg М. С. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr. and Rheum. 1997; 40: 1725-1734.
- Bombardier C., Gladman D. D., Urowitz M. B. et al. Derivation of the SLEDAI (a disease activity index for lupus patients). Arthr. and Rheum. 1992; 35: 630-640.
- Gladman D. D., Goldsmith С. H., Urowitz M. B. et al. The Systemic Lupus Erythematosus Collaborating Clinics / American College of Rheumatology index for systemic lupus erythematosus international comparison. J. Rheumatol. 2000; 27: 373-376.
- Exspert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) exspert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult treatment panel III). JAMA 2001; 285: 2486-2497.
- Перова H. В. Суммарный коронарный риск ИБС и показания к лечению гиперхолестеринемии (применение Европейских рекомендаций к российским условиям). Кардиология 1996; 49-53.
- Диагностика и лечение стабильной стенокардии: Российские рекомендации ВНОК. М.; 2004. 7-11.
- Haward G., Sharrett А. R., Heiss G. et al. Carotid artery intima-media thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 1993; 24: 1297-1304.
- Ianuzzi A., Michele M. D., Panico S. et al. Radical-trapping activity, blood pressure and carotid enlargement in women. Hypertension 2003; 41: 289-296.
- Artiss J. D., Zak B. Measurement of cholesterol concentration. In: Rifai N., Warmic G. R., Dominiczak M. H., eds. Handbook of lipoprotein testing. Washington: AACC Press; 1997. 99-114.
- Friedwald W. Т., Levy R. J., Fredrickson D. S. Estimation of the calculation of LDL cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 1972; 18: 499-502.
- Aukrust P. A., Muller F. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndrome. Circulation. 1999; 100: 614-620.
- Garlichs С. D., Eskafi S., Raaz D. et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD454 on platelets. Heart 2001; 86: 649-655.
- Nannizzi-Alaimo L., Rubenstein M. H., Alvos V. L. et al. Cardiopulmonary bypass induces the release of soluble CD40 ligand. Circulation 2002; 105: 2849-2854.
- Tsakis D. A., Tschopl M., Wolf F. et al. Platelets and cytokines in concert with endothelin activation in patients with peripheral arterial occlusive disease. Blood Coagul. Fibrinolys. 2000; 11: 165-173.
- Garlichs C. D., Kozina S., Fateh-Moghadam S. et al. Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003; 34: 1412-1418.
- Heeschen C., Dimmeler S., Hamm С. V. et al. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 2003; 348: 1104-1111.
- Schönbeck U., Varo N., Libby P. et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-2268.
- Scalzi V. V., Cron R. C., Von Feldt J. M. Correlation of increased soluble CD40 ligand levels and coronary artery calcification in SLE patients (abstract). Arthr. and Rheum. 2002; 45 (suppl. 9): 55.
![](/img/style/loading.gif)